Navigation Links
Vanderbilt Medical Center Seeks Middle Tennesseans with Type 2 Diabetes Who are Overweight for National Clinical Trial
Date:12/10/2007

NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- Vanderbilt Medical Center is seeking local residents with type 2 diabetes who are overweight to participate in a national clinical study evaluating an investigational device, the TANTALUS System. Diabetes affects more than 400,000 individuals in Tennessee.

The TANTALUS System is an implantable device that delivers electrical pulses to the stomach when a person eats. The primary objective of the randomized, double-blind controlled study is to evaluate the safety and efficacy of the TANTALUS System in treating patients who have type 2 diabetes and are overweight. Impact on weight loss, blood pressure and other clinical and metabolic parameters will also be studied.

TANTALUS includes a pulse generator and leads that are implanted through a minimally invasive laparoscopic procedure that can be performed in an outpatient setting. The leads are implanted in the gastric muscle and the device is implanted in a subcutaneous pocket. The system is based on new technology called Gastric Contractility Modulation (GCM) that is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation treatment during meal times.

To be considered for the trial, patients must meet certain inclusion criteria, including a diagnosis of type 2 diabetes (treated with oral medications, only), a body mass index (BMI) between 28 and 45, and be between 18 and 70.

"Even with current medications and lifestyle changes, controlling blood glucose levels in type 2 diabetes patients who are overweight can be difficult, " explained study investigator William Richards, M.D. "We are excited to be participating in this clinical trial of an alternative treatment for patients where we have been unsuccessful in managing their type 2 diabetes and weight."

The national epidemic of type 2 diabetes, most often associated with being overweight, continues to accelerate and affects more than 20 million Americans. About 1 million new people are diagnosed with the disease annually. Each year, it costs the nation more than $130 billion in hospitalizations, co- morbidities and loss of productivity.

For more information on and to be considered for the study, please call Joan Kaiser at (615) 343-5821.

For More Information:

Jerry Jones

(615) 322-4747

jerry.jones@vanderbilt.edu


'/>"/>
SOURCE Vanderbilt Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):